Vanguard Group
AVEO

Vanguard Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Vanguard Group’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,513,400
Closed -$22.6M – 4664
2022
Q4 		$22.6M Buy
1,513,400
+5,445
+0.4% +$75.4K ﹤0.01% 2560
2022
Q3 		$12.4M Buy
1,507,955
+6,638
+0.4% +$51K ﹤0.01% 2846
2022
Q2 		$9.85M Hold
1,501,317
– – ﹤0.01% 3000
2022
Q1 		$8.39M Buy
1,501,317
+36,210
+2% +$149K ﹤0.01% 3247
2021
Q4 		$6.87M Buy
1,465,107
+8,877
+0.6% +$55.1K ﹤0.01% 3436
2021
Q3 		$9M Buy
1,456,230
+8,544
+0.6% +$51.1K ﹤0.01% 3305
2021
Q2 		$9.54M Buy
1,447,686
+75,149
+5% +$518K ﹤0.01% 3229
2021
Q1 		$10M Buy
1,372,537
+120,390
+10% +$1.04M ﹤0.01% 3140
2020
Q4 		$7.22M Buy
1,252,147
+153,798
+14% +$880K ﹤0.01% 3162
2020
Q3 		$6.52M Buy
1,098,349
+14,083
+1% +$69.7K ﹤0.01% 3014
2020
Q2 		$5.58M Buy
1,084,266
+430,258
+66% +$2.72M ﹤0.01% 3046
2020
Q1 		$2.37M Buy
654,008
+6,500
+1% +$32.3K ﹤0.01% 3258
2019
Q4 		$4.04M Buy
647,508
+947
+0.1% +$6.97K ﹤0.01% 3237
2019
Q3 		$5.46M Sell
646,561
-120,449
-16% -$896K ﹤0.01% 3108
2019
Q2 		$5.16M Buy
767,010
+161,481
+27% +$1.38M ﹤0.01% 3164
2019
Q1 		$4.97M Buy
605,529
+82,001
+16% +$847K ﹤0.01% 3149
2018
Q4 		$8.38M Buy
523,528
+16,892
+3% +$372K ﹤0.01% 2853
2018
Q3 		$16.8M Buy
506,636
+7,352
+1% +$189K ﹤0.01% 2666
2018
Q2 		$11.3M Buy
499,284
+47,364
+10% +$1.12M ﹤0.01% 2844
2018
Q1 		$13.1M Buy
451,920
+16,410
+4% +$480K ﹤0.01% 2684
2017
Q4 		$12.2M Buy
435,510
+9,118
+2% +$283K ﹤0.01% 2728
2017
Q3 		$15.6M Buy
426,392
+71,256
+20% +$2.2M ﹤0.01% 2594
2017
Q2 		$7.88M Buy
355,136
+116,223
+49% +$915K ﹤0.01% 2893
2017
Q1 		$1.41M Sell
238,913
-7,062
-3% -$51K ﹤0.01% 3491
2016
Q4 		$1.33M Buy
245,975
+3,916
+2% +$26.1K ﹤0.01% 3490
2016
Q3 		$2.15M Sell
242,059
-4,990
-2% -$47K ﹤0.01% 3361
2016
Q2 		$2.37M Buy
247,049
+2,731
+1% +$26.3K ﹤0.01% 3321
2016
Q1 		$2.25M Buy
244,318
+12,137
+5% +$120K ﹤0.01% 3325
2015
Q4 		$2.92M Buy
232,181
+9,578
+4% +$114K ﹤0.01% 3238
2015
Q3 		$2.69M Buy
222,603
+9,931
+5% +$144K ﹤0.01% 3241
2015
Q2 		$3.7M Buy
212,672
+3,824
+2% +$68.8K ﹤0.01% 3151
2015
Q1 		$3.03M Buy
208,848
+25,746
+14% +$281K ﹤0.01% 3227
2014
Q4 		$1.54M Buy
183,102
+19,047
+12% +$174K ﹤0.01% 3375
2014
Q3 		$1.82M Buy
164,055
+16,958
+12% +$216K ﹤0.01% 3310
2014
Q2 		$2.69M Sell
147,097
-5,965
-4% -$77.6K ﹤0.01% 3122
2014
Q1 		$2.29M Buy
153,062
+22,309
+17% +$401K ﹤0.01% 3161
2013
Q4 		$2.41M Sell
130,753
-19,349
-13% -$387K ﹤0.01% 3115
2013
Q3 		$3.11M Buy
150,102
+4,285
+3% +$98.1K ﹤0.01% 2958
2013
Q2 		$3.65M Buy
+145,817
New +$6.23M ﹤0.01% 2836

Vanguard Group's AVEO Position: Q1 2023 in Review

Vanguard Group sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 1,513,400 shares — an estimated $22.6M sold.

Vanguard Group first reported a position in AVEO in Q2 2013 and held it in 39 quarters. The position peaked at $22.6M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Vanguard Group reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 1,513,400 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $22.6M.
  • Vanguard Group first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 39 quarters.
  • Vanguard Group's AVEO Pharmaceuticals, Inc. position peaked at $22.6M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.